News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CardiacAssist, Inc. Receives FFA Sciences IDE Approval for Use of the TandemHeart System in Pivotal Clinical Study


12/18/2012 9:10:23 AM

PITTSBURGH--(BUSINESS WIRE)--CardiacAssist, Inc., a privately-held medical technology company headquartered in Pittsburgh, Pennsylvania, announced today that it received Investigational Device Exemption (IDE) approval from the Food & Drug Administration (FDA) for a pivotal clinical study of the TandemHeart circulatory support system. The TandemHeart to Reduce Infarct Size (TRIS) Trial will evaluate the effectiveness of ventricular unloading on the reduction of infarct size for patients who have suffered a severe heart attack.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES